Q3 2024 Ascelia Pharma AB Earnings Call Transcript
Key Points
- Ascelia Pharma AB (FRA:7ZA) successfully completed a pivotal phase three clinical study for Orby Gland, advancing it to the regulatory phase with an NDA submission planned for mid-2025.
- The company raised SEK105 million through a fully subscribed rights issue, providing a cash runway until late 2025.
- Orby Gland addresses a significant unmet medical need in liver MRI for patients with severe kidney impairment, targeting an $800 million global market.
- The Sparkle study demonstrated that Orby Gland provides superior imaging compared to unenhanced MRI, with statistically significant results.
- Ascelia Pharma AB (FRA:7ZA) is actively pursuing commercialization partnerships to optimize the launch and revenue potential of Orby Gland.
- The company faces a lengthy and complex NDA submission process, with a standard 10-month review period anticipated from the FDA.
- There is uncertainty regarding the potential for priority review by the FDA, which could impact the timeline for Orby Gland's approval.
- Ascelia Pharma AB (FRA:7ZA) has not yet secured a commercialization partner, which is crucial for the successful launch of Orby Gland.
- The company's operating loss increased to SEK17.8 million in Q3, driven by costs associated with NDA preparations.
- There is a risk associated with the reliance on external resources and CROs for the NDA submission process, which could affect timelines and costs.
Thank you and welcome everyone to the webcast for CF MS Q3 report for 2024 on this call, we will be making forward-looking statements on today's call. We will start with recent key events and then head into our portfolio update before moving to financials and priorities ahead.
After the presentation, we will open up for questions at Elia Pharma. We identify, develop and commercialize novel drugs that address unmet medical needs within rare cancer conditions.
We have two drugs in our pipeline.
Orby Gland is in registration phase as we have successfully completed the pivotal phase three clinical study. Sparkle and we're preparing the ND A submission.
Orby GL has often dropped designation from the FDA and is targeting an addressable market opportunity of $800 million.
Oncol is ready to start phase two in the treatment of gastric cancer based on encouraging results in phase one and a high level of unmet medical need.
Aelia farmer is based in Malur Sweden and we are listed on NASDAQ.com.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
